Phase 3 Lung Cancer Trial, Not Yet Recruiting NCT06961188 Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. Condition: Lung Cancer
Back to Lung Cancer

Phase 3 Lung Cancer Trial, Not Yet Recruiting

NCT06961188
Not Yet Recruiting Phase 3

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who are 18 years of age or older at the time of joining the trial.
  • People whose general health and ability to carry out daily activities falls within a certain range, as measured by a standard oncology scoring tool called the ECOG scale (scores 0–2, meaning fully active to capable of limited self-care — confirm with trial site if unsure where someone falls on this scale).
  • People who are expected to live for at least 6 months.
  • People who have been confirmed through tissue or cell testing to have a specific type of advanced (stage IV) lung cancer — non-squamous non-small cell lung cancer (NSCLC) — that has spread to other parts of the body, cannot be removed by surgery, and cannot be cured with current treatments, and whose cancer does not have certain gene changes (driver gene-negative).
  • People who have not yet received any chemotherapy given throughout the body (systemic chemotherapy) for their advanced lung cancer.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have conditions that affect how the body absorbs food or medication through the digestive system, such as difficulty swallowing, poor nutrient absorption, previous stomach removal surgery, or vomiting that cannot be controlled; or who are currently on tube feeding or intravenous nutrition; or who have anorexia nervosa, an eating problem caused by a psychiatric condition, or an inability to eat due to pain.
  • People whose lung cancer is driven by specific gene changes (driver gene-positive), or whose cancer has been confirmed through testing to be mainly squamous cell type.
  • People who have Cushing's syndrome, problems with the adrenal or pituitary glands, or diabetes that is not well controlled.
  • People who are currently taking part in another clinical trial that involves an active treatment or intervention (observational studies or the follow-up stage of a previous trial may be acceptable — confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 9 July 2026

Contact this trial

Phone: 13986252286

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 3
Sponsor
Changchun GeneScience Pharmaceutical Co., Ltd.
Registry
ClinicalTrials.gov
Start date
1 June 2025
Est. completion
30 June 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Proportion of appetite improvement assessed by A/CS-12 (Anorexia/Cachexia Subscale of Functional Assessment of Anorexia/Cachexia Therapy); Proportion of individuals with weight gain exceeding 5% relative to baseline

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov